Stockscreener 앱 받기
8.17
0.12%
-0.010
시간 외 거래:
8.17
전일 마감가:
$8.18
열려 있는:
$8.24
하루 거래량:
805.53K
Relative Volume:
0.60
시가총액:
$795.67M
수익:
-
순이익/손실:
$-137.25M
주가수익비율:
-4.3228
EPS:
-1.89
순현금흐름:
$-121.97M
1주 성능:
-0.97%
1개월 성능:
-23.29%
6개월 성능:
-23.29%
1년 성능:
-1.09%
1일 변동 폭
$8.04
$8.33
1주일 범위
$7.955
$8.44
52주 변동 폭
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.17 | 796.64M | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cuts2025 Market WrapUp & Reliable Trade Execution Plans - Улправда
Market Overview: How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsWatch List & Safe Entry Trade Reports - Улправда
Why ORIC Pharmaceuticals Inc. stock attracts global investorsM&A Rumor & Growth Focused Investment Plans - DonanımHaber
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
How strong is ORIC Pharmaceuticals Inc. stock revenue growth2025 Momentum Check & AI Powered Market Entry Ideas - Улправда
ORIC Pharmaceuticals Earnings Notes - Trefis
Oric Pharmaceuticals (NASDAQ:ORIC) Insider Pratik Multani Sells 10,720 Shares - MarketBeat
Dominic Piscitelli Sells 10,720 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells 33,374 Shares - MarketBeat
[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Oric Pharmaceuticals Executives Conduct Stock Transactions - TradingView — Track All Markets
Oric Pharmaceuticals President and CEO Sells Shares - TradingView — Track All Markets
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.5%Here's What Happened - MarketBeat
CFO Piscitelli Files To Sell 10,720 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value - Insider Monkey
20 Stocks That Will Double in 2026 - Insider Monkey
Frazier Life Sciences Management L.P. Sells 344,859 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals Advances Key Cancer Drug Toward Late-Stage Trials - AD HOC NEWS
Oric Pharmaceuticals, Inc. $ORIC Shares Sold by EcoR1 Capital LLC - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
Stempoint Capital LP Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Dir Kunkel Acquires 10,000 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
Vivo Capital LLC Has $31.74 Million Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Resolute Capital Asset Partners LLC Invests $2.31 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Wells Fargo maintains ORIC Pharmaceuticals (ORIC) overweight recommendation - MSN
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Analyst Rating Update from Wells Fargo | ORIC Stock News - GuruFocus
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wedbush Reiterates 'Outperform' Rating for ORIC Pharmaceuticals - GuruFocus
Wells Fargo raises ORIC Pharmaceuticals stock price target on promising cancer drug data - Investing.com Canada
Oric Pharmaceuticals, Inc. Presents Enozertinib Program Update - TradingView
JPMorgan Chase & Co. Raises Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals (ORIC) Showcases Promising Phase 1b Trial D - GuruFocus
Oric Pharmaceuticals presents data from enozertinib trial at ESMO Asia - MSN
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 - Sahm
Fund Flows: Will ORIC Pharmaceuticals Inc stock see PE expansionPortfolio Growth Summary & Growth Focused Investment Plans - moha.gov.vn
Head to Head Survey: Oric Pharmaceuticals (NASDAQ:ORIC) & LENZ Therapeutics (NASDAQ:LENZ) - Defense World
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - The Manila Times
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Multani Pratik S | Chief Medical Officer |
Dec 16 '25 |
Sale |
9.06 |
10,720 |
97,129 |
68,149 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '25 |
Option Exercise |
0.00 |
29,333 |
0 |
78,868 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '25 |
Sale |
9.06 |
10,720 |
97,127 |
68,148 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '25 |
Option Exercise |
0.00 |
83,666 |
0 |
615,085 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '25 |
Sale |
9.06 |
33,374 |
302,368 |
581,711 |
0.57%
자본화:
|
볼륨(24시간):